FORTREA HOLDINGS DL-,001 Aktie Logo
US34965K1079
A3ECGB
FTRE

FORTREA HOLDINGS DL-,001 Aktie

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 21,33 € (+19,16%). La mediana è 21,38 € (+19,44%).

Acquista
  7
Mantieni
  5
Vendi
  1

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Fortrea cooperates with Omico to accelerate biomarker-driven cancer trials in Australia

    Fortrea has announced a collaboration with Omico to advance precision oncology research by accelerating the identification and matching of suitable patients to biomarker-driven clinical trials. The partnership combines Fortrea’s expertise in running oncology studies with Omico’s PrOSPeCT platform, molecular profiling data and a network of investigators and trial sites in Australia. The aim is to optimize study design, enable more targeted site selection and speed patient recruitment using genomic data from more than 23,000 patients. » Altro su finanzen.net


  • Fortrea completes acquisition of Worldwide Clinical Trials' early phase services business

    Fortrea has closed the purchase of Worldwide Clinical Trials' early phase services division for about $45 million. The deal includes a 200-bed CRU in San Antonio, a 60,000 sq ft GLP bioanalytical lab in Austin and a sample storage facility in Pflugerville. The acquisition brings Fortrea's global early-phase capacity to more than 570 beds and strengthens internal bioanalytical capabilities to better integrate clinical and analytical processes. It is intended to shorten turnaround times, reduce operational handoffs and expand the platform for clinical development. » Altro su finanzen.net


  • Fortrea buys early-phase unit from Worldwide for $45 million

    Fortrea has signed an agreement to acquire the early‑phase division of Worldwide Clinical Trials for about $45 million in cash. The acquisition includes a 60,000‑square‑foot bioanalytical lab in Austin, a 200‑bed clinic in San Antonio and a biospecimen storage facility in Pflugerville. Fortrea thereby strengthens its Clinical Pharmacology Services and expands capacity for bioanalysis of large and small molecules, while the transaction still requires regulatory and licensing approvals. Both companies plan transition agreements to ensure continuity for customers and ongoing programs. » Altro su de.investing.com


  • Fortrea introduces Fortrea Intelligent Technology, an AI-powered suite to accelerate clinical trials

    Fortrea has introduced Fortrea Intelligent Technology (FIT), a suite of people-centered, AI-powered solutions to automate workflows, optimize monitoring, and accelerate clinical trials. FIT builds on the Xcellerate platform and offers applications for biopharma, biotechnology, and medical device companies in full-service, functional-service, and SaaS models. The suite is organized into three pillars — lifecycle, foresight, and support — and provides role-based insights in near real time to improve predictability, quality, and productivity. » Altro su finanzen.net


  • Fortrea launches AI-powered technology suite Fortrea Intelligent Technology to support clinical trials

    Fortrea introduced Fortrea Intelligent Technology (FIT), an AI-powered suite that includes extensions to the Xcellerate platform and new Lifecycle, Foresight and Companion modules. The tools automate workflows, integrate study data for role-specific insights and use AI/ML for pattern analysis and predictive signal generation; selected components will be offered as SaaS. The announcement comes as the stock trades below $10 and analysts project a return to profitability. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, FORTREA HOLDINGS DL-,001 Aktie ha registrato ricavi pari a 610,49 Mln € e un utile netto di 529,71K €
(EUR) settembre 2026
YoY
Ricavi 610,49 Mln 2,16%
Utile lordo 123,16 Mln 40,18%
Utile netto 529,71K 103,91%
EBITDA 32,31 Mln 180,88%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
1,69 Mld €
Numero di azioni
94,6 Mln
Massimo/minimo a 52 settimane
23,80 € - 7,78 €
Dividendi No
Beta
1,86
Rapporto P/E
-25,99
Rapporto PEG
-0,11
Rapporto P/B
3,52
Rapporto P/S
0,69

Profilo aziendale

Fortrea Holdings Inc. fornisce soluzioni per lo sviluppo clinico e l'accesso dei pazienti al settore delle scienze della vita. Offre la gestione di studi clinici di fase I-IV, farmacologia clinica, soluzioni per la sperimentazione clinica differenziate e basate sulla tecnologia, e servizi post-approvazione. L'azienda si rivolge a organizzazioni farmaceutiche, biotecnologiche e di dispositivi medici. Fortrea Holdings Inc. ha sede a Durham, nella Carolina del Nord.

Nome
FORTREA HOLDINGS DL-,001 Aktie
CEO
Anshul Thakral
Sede centrale Durham, nc
Stati Uniti
Sito web
Industria
Attrezzature e forniture sanitarie
Quotazione in borsa
20/06/2023
Dipendenti 14.000

Simboli di borsa

Borsa Simbolo
NASDAQ
FTRE
Frankfurt
K67.F
Düsseldorf
K67.DU
München
K67.MU
🍪

Parqet  usa i cookie. Scopri di più